Information Services Group (III) – Another Solid Quarter

Tuesday, August 09, 2022

Information Services Group (III)
Another Solid Quarter

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For additional information, visit www.ISG-One.com

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

More Records. ISG announced revenue of $70.7 million for the second quarter, flat with the $70.6 million in the year ago period. On a constant currency basis, revenue rose 5%. The quarter had record net income of $5.0 million, or $0.10 fully diluted EPS, versus $4.1 million and $0.08 the previous year. Adjusted EBITDA also was a record at $10.7 million, a 10% increase year-over-year.

Quarterly Drivers. Revenue was negatively impacted by a higher forex headwind than anticipated. In addition, the completion of a large Automation contract and relatively soft environment in the vertical negatively impacted overall revenue. Nonetheless, ISG continues to see growing demand for specialized services like cybersecurity, data analytics, application development, and technology modernization as well as an increased focus from clients on cost optimization….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Gevo (GEVO) – Management makes case that market is bigger than expected

Tuesday, August 09, 2022

Gevo (GEVO)
Management makes case that market is bigger than expected

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel, and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full lifecycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their lifecycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented, technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low carbon products such as gasoline components, jet fuel, and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Gevo reported 2022-2Q results generally in line with expectations. Revenues are modest ($0.1m vs. $0.3m and our $1.0m est.). Operating costs have become more stable and predictable leading to steady EBITDA losses ($11.0m vs. $17.2m and our $11.4m est.). Net losses met expectations ($16.1m or $0.06 p/s vs. $19.1m or $0.09 p/s and our $14.0m or $0.06 p/s). The real story, however, is not near-term results but plant developments, financing, and contract signings.

Gevo was active in all aspects of the business. The company signed five new take-or-pay jet fuel contracts and now totals 350m gal./year or $2.2 billion. This is more contracted outtake than the projected NZ1 plant production. Management’s vision is to use NZ1 to demonstrate economics but has a clear eye on replicating the project. In fact, it plans to continue to sign contracts for production beyond 2027. Speaking of NZ1, Gevo has recently purchased land for the plant and says it is on schedule for a 2025 start-up….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

ACCO Brands (ACCO) – First Look: 2Q22

Tuesday, August 09, 2022

ACCO Brands (ACCO)
First Look: 2Q22

ACCO Brands Corporation is one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products. Our widely recognized brands include AT-A-GLANCE®, Esselte®, Five Star®, GBC®, Kensington®, Leitz®, Mead®, PowerA®, Quartet®, Rapid®, Rexel®, Swingline®, Tilibra®, and many others. Our products are sold in more than 100 countries around the world. More information about ACCO Brands, the Home of Great Brands Built by Great People, can be found at www.accobrands.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q22 Operating Results. ACCO reported 2Q22 revenue of $521 million, up 0.6% year-over-year and up 5.2% on a comparable basis, with all segments posting growth. ACCO has now recorded five consecutive quarters of comparable sales growth. We had forecast revenue of $545 million. Adjusted EPS was $0.37, compared to $0.43 last year. We had forecast adjusted EPS of $0.44.

Forex, Economic Conditions Restrain Growth. Slower economic growth, increased inflation, and unfavorable foreign currency impacts resulted in a more challenging quarter than anticipated. Adverse foreign exchange reduced sales by $23.6 million in the quarter, while a lack of computer chips resulted in lower sales of gaming accessories. Operating income benefited from $9.4 million of contingent earnout income related to the PowerA acquisition….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Pyxis Tankers (PXS) – Outstanding quarter shows sensitivity to shipping rates

Tuesday, August 09, 2022

Pyxis Tankers (PXS)
Outstanding quarter shows sensitivity to shipping rates

We currently own a modern fleet of five tankers engaged in seaborne transportation of refined petroleum products and other bulk liquids. We are focused on growing our fleet of medium range product tankers, which provide operational flexibility and enhanced earnings potential due to their “eco” features and modifications. We are positioned to opportunistically expand and maximize our fleet due to competitive cost structure, strong customer relationships and an experienced management team whose interests are aligned with those of its shareholders. For more information, visit: http://www.pyxistankers.com.

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Pyxis reported strong top-line results due to higher shipping rates. Results carried through to earnings. Pyxis reported 2022-2Q net revenues of $16.1 million vs. $7.7 million for the same period last year as higher energy prices and a disruption in global oil flow routes due to the Russia/Ukraine war resulted in higher tanker shipping rates. The average TCE rate for the quarter was $21,070 vs. $12,280 and could go higher in the third quarter with 57% of capacity fixed at $30,500. Meanwhile, operating costs per day declined to $6,181 from $6,697 leading to net income of $4.6 million or $0.38 per diluted versus ($1.4 million) or ($0.16 per share).

Cash flow is strong and the balance sheet is reasonable. Adjusted EBITDA was $7.3 million up from $0.4 million. The company’s cash position has grown to $6.2 million with $73.8 million in debt. Debt represents approximately 60% of capitalization (net debt is 55%). Debt is well supported by a increasingly more valuable asset base. Financing costs are an average 4.6%. The utilization rate for the quarter was 98%, a large improvement above first quarter rates of 74% that suffered from the accidental grounding of a tanker….

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Tonix Pharmaceuticals (TNXP) – Second Quarter Saw Progress In Several Therapeutic Areas

Tuesday, August 09, 2022

Tonix Pharmaceuticals (TNXP)
Second Quarter Saw Progress In Several Therapeutic Areas

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-15001 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL6, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13007 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q Reported With Product Milestones Ahead.  Tonix reported a loss of $27.4 million or $(1.22) per share compared with our estimated loss of $26.9 million or $(1.43) per share.  During the quarter the company raised $28.5 million in a private placement, ending with $145.5 million in cash on June 30.

Monkeypox Program Has Become A New Focus.  Tonix announced that it formed a collaboration with the Kenya Medical Research Institute for a Phase 1 trial to start in 1H2023.   Tonix has been developing TNX-801, a vaccine that has been shown to be effective against both smallpox and monkeypox in preclinical testing with non-human primates.  We have always seen the potential for TNX-801 as an improved smallpox vaccine that would be sold to the US government stockpile for use defense against bioterrorism.  Since Monkeypox has been declared a public health emergency, monkeypox prevention could bring additional sales beyond our estimates….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – V2X (Formerly Vectrus) Reports Strong Second Quarter 2022 Results



V2X (Formerly Vectrus) Reports Strong Second Quarter 2022 Results

Research, News, and Market Data on V2X

Company Release – 
8/9/2022

Important Note: On July 5, 2022, Vectrus, Inc. closed on the
merger with The Vertex Company (“the Transaction”) and in connection
with the closing was renamed V2X, Inc. “Reported results” reflect the
contributions of Vectrus, Inc. based on results prior to the close of the
Transaction, unless otherwise noted.

Vectrus Second Quarter Highlights:

  • Second quarter revenues of $498 million, up +6% Y/Y
  • Operating income (inclusive of V2X transaction expenses) of $15.0 million with a margin of 3.0%
  • Adjusted EBITDA1 of $24.7 million with a margin of 5.0%
  • Second quarter fully diluted EPS of $0.88; Adjusted diluted EPS1 of $1.41
  • Strong second quarter operating cash flow of $46 million

Guidance:

  • The V2X merger closed on July 5, 2022, creating a more diversified company generating approximately $3.6 billion in combined pro forma annual revenue
  • Establishing second-half 2022 guidance for V2X that reflects the contributions of both Vectrus and Vertex with a total revenue range of $1.90 to $1.94 billion, an Adjusted EBITDA1 range of $140 to $150 million, and an operating cash flow range of $130 to $150 million

MCLEAN, Va., Aug. 9, 2022 /PRNewswire/ — V2X, Inc. (NYSE:VVX) announced second quarter 2022 financial results. The second quarter 2022 results are based on Vectrus’ stand-alone financial metrics for the period ended July 1, 2022, and do not include contribution from The Vertex Company.

V2X (PRNewsfoto/V2X, Inc.)

Transaction
Update

“We’re excited to announce the successful combination of Vectrus and The Vertex Company, creating a larger, higher margin and more diversified, V2X,” said Chuck Prow, Chief Executive Officer of V2X.  “With 14,000 employees, $3.6 billion in pro forma annual revenue, and $290 million of Adjusted EBITDA, V2X is a leader in the operational segment of the federal services market providing converged solutions throughout the mission lifecycle of our clients most critical and enduring global missions.”

Prow continued, “V2X has a strong financial profile with significant free cash flow and long-term revenue visibility through several notable contract wins that are in the early stages of their lifecycle. These wins are reflected in the company’s trailing twelve-month awards of approximately $6 billion, which include two recent significant awards at Vertex, the Naval Test Wing Atlantic, a seven-year program valued at $850 million, and the Air Force Global Strike Command five-year contract valued at $130 million. This also includes $600 million of awards booked at Vectrus during the quarter that were driven by expansion and increased scope on existing programs as well as follow-on contracts. The strong velocity of awards has resulted in a significant backlog of approximately $12 billion that provides solid visibility over the next several years.”

“In summary, the financial and strategic attributes of V2X are compelling,” added Prow. “Our integration activities are well underway and the commitment to our clients, the missions we are privileged to support, and delivering results remains our focus.”

Vectrus
Second Quarter Results

“Second quarter results for stand-alone Vectrus were strong, propelled by top-line performance and favorable operating cash flow,” said Prow.  “During the quarter, revenue grew 6% year-over-year and 9% sequentially to $498 million. Revenue growth was driven by building on the momentum of programs in INDOPACOM and Europe, along with successful phase-in of new contracts, including the Logistics Readiness Center at Fort Benning,” said Prow.  “Each day, our global team of dedicated employees execute on our core programs while also bringing innovation and technology-oriented solutions to complex challenges throughout the mission lifecycle.”  

“With a high-level readiness to meet the needs of our clients, the team continued its support of several important missions during the quarter, including providing the DoD with urgent and compelling services for the European Deterrence Initiative,” said Prow. “We leveraged our rapid response capability and over 40-year history of operating in Europe to provide the DoD with unique services in support of this complex and ongoing mission. Additionally, achieving full operational capability on LOGCAP V Kwajalein, approximately a month and a half ahead of schedule, has helped to expand our footprint in the INDOPACOM region. Activity in the region remains robust and our position continues to expand. For example, we recently expanded our scope of responsibilities at Subic Bay in the Philippines.  This program is expected to run over the next eight years and provides strategic logistics services to the DoD.  Work content in the INDOPACOM region now represents 9% of total revenue, up 3% from last year, and positions us well to support the DoD in a full range of operations over the next ten years.”

“Adjusted EBITDA for the quarter was strong at $24.7 million or 5.0% margin.  Adjusted EBITDA increased sequentially $6.5 million and was driven by higher revenue volume and success on operational excellence initiatives.  We remain focused on margin improvement, and this quarter’s results reflect our ability to expand earnings even as we execute on several programs in the early phases of period of performance. As we have noted in the past, LOGCAP V is generating higher revenue volume with a greater amount of material and pass-through content that has a different margin complexion. However, our teams are focused on driving program efficiencies and improving margin rates through contract add-on work while working with clients to convert certain components of work to more advantageous contract structures.”

Prow concluded, “Our second quarter results demonstrate the Company’s success in achieving top-line growth through increased work scope on existing programs, expansion of capabilities, broadening our geographic footprint, and adding new clients.  As we embark on the Company’s new chapter as V2X, I am excited about the greater scale, market leadership, and enhanced portfolio of offerings with the Vectrus/Vertex combination.”

Second quarter 2022 revenue of $498.1 million was up $27.2 million year on year.  “Revenue grew 6% year-over-year, driven by our transition to full operational capability on LOGCAP V programs in Iraq and Kuwait late last year, and INDOPACOM this year. In addition, revenue benefitted from transitioning Fort Benning and volume associated with rapid response and contingency efforts,” said Susan Lynch, Senior Vice President and Chief Financial Officer. “This revenue growth demonstrates achievement of our enterprise goal of growing the business through contract expansion and portfolio diversity despite the headwinds associated with the withdrawal of the US military from Afghanistan,” added Lynch. 

Operating income was $15.0 million or 3.0% margin.  This includes M&A and integration related expenses of $5.9 million and amortization of acquired intangible assets of $2.1 million which were incurred in the quarter.  Adjusted operating income1 was $23.0 million or 4.6% margin, increasing sequentially by $6.4 million and 100 basis points.  Adjusted EBITDA1 was $24.7 million or 5.0% margin, increasing sequentially by $6.5 million and 100 basis points.  Adjusted EBITDA margin compares to $26.6 million or 5.6% in the prior year period. “The year-on-year margin change was influenced by the significant amount of revenue and contracts that are in the early stages of their lifecycle.  In aggregate, on average and over time, we expect to see improvement in the margin profile as we drive operational efficiencies and diversify into higher margin scopes of work,” said Lynch.

Fully diluted EPS for the second quarter of 2022 was $0.88 as compared to $1.35 in the prior year.  Fully diluted EPS in the quarter included the aforementioned M&A and integration related costs.  Adjusted diluted EPS1 was $1.41 in the quarter as compared to $1.52 in the prior year. The year-on-year change in Adjusted diluted EPS1 was primarily due to the above-mentioned change in Adjusted EBITDA1.

Cash generated from operating activities for the quarter was $46.0 million.  Through July 1, 2022, net cash from operating activities was $19.6 million, compared to net cash from operating activities of $14.0 million through the second quarter of 2021. Cash from operating activities through the first half of 2022 was negatively impacted by an approximately $8.0 million repayment of CARES Act tax deferrals and $5.8 million of merger-related payments.

Net debt on July 1, 2022, was $58.4 million, compared to $105.2 million on July 2, 2021.  Total debt on July 1, 2022, was $90.2 million, down $84.8 million from $175.0 million on July 2, 2021. Cash at quarter-end was $35.1 million.  Total consolidated indebtedness to consolidated EBITDA1 (total leverage ratio) was 1.09x compared to 1.76x at the same time last year.

Total backlog as of July 1, 2022, was $4.6 billion.  Funded backlog was $1.3 billion. 

V2X
Guidance

Lynch continued, “We are establishing second half 2022 guidance ranges for V2X, which includes the contribution from both Vectrus and The Vertex Company.”

V2X guidance for the second half (2H) 2022 is as follows:

$
millions, except for EBITDA margins and per share amounts

V2X 2H 2022 Guidance

Revenue

$1,900

to

$1,940

Adjusted EBITDA1

$140

to

$150

Adjusted Diluted Earnings Per Share 1

$1.94

to

$2.19

Net Cash Provided by Operating Activities

$130

to

$150

Forward-looking statements are based upon current expectations and are subject to factors that could cause actual results to differ materially from those suggested here, including those factors set forth in the Safe Harbor Statement below. 

Second Quarter 2022 Conference Call

Management will conduct a conference call with analysts and investors at 4:30 p.m. ET on Tuesday, August 9, 2022. U.S.-based participants may dial in to the conference call at 877-242-2259, while international participants may dial 416-981-9017. A live webcast of the conference call as well as an accompanying slide presentation will be available on the Vectrus Investor Relations website at https://app.webinar.net/P4Qe37VDnop.

A replay of the conference call will be posted on the V2X website shortly after completion of the call and will be available for one year. A telephonic replay will also be available through August 23, 2022, at 844-512-2921 (domestic) or 412-317-6671 (international) with passcode 22020062.    

Footnotes:

1 See “Key Performance Indicators and Non-GAAP Financial Measures” for descriptions and reconciliations.

About V2X

V2X is a leading provider of critical mission solutions and support to defense clients globally, formed by the 2022 merger of Vectrus and The Vertex Company to build on more than 120 combined years of successful mission support. The Company delivers a comprehensive suite of integrated solutions across the operations and logistics, aerospace, training and technology markets to national security, defense, civilian and international clients. Our global team of approximately 14,000 employees brings innovation to every point in the mission lifecycle, from preparation, to operations, to sustainment, as it tackles the most complex challenges with agility, grit, and dedication.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 (the “Act”): Certain material presented herein includes forward-looking statements intended to qualify for the safe harbor from liability established by the Act. These forward-looking statements include, but are not limited to, all the statements and items listed in the table in “2022 Guidance” above and other assumptions contained therein for purposes of such guidance, other statements about our 2021 performance outlook, five-year growth plan, revenue, DSO, contract opportunities, the potential impact of COVID-19, and any discussion of future operating or financial performance.

Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “could,” “potential,” “continue” or similar terminology. These statements are based on the beliefs and assumptions of the management of the Company based on information currently available to management.

These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside our management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.  In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Company’s historical experience and our present expectations or projections. For a discussion of some of the risks and important factors that could cause actual results to differ from such forward-looking statements, see the risks and other factors detailed from time to time our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission.

We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

V2X, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

Three Months Ended

Six Months Ended

July 1,

July 2,

July 1,

July 2,

(In
thousands, except per share data)

2022

2021

2022

2021

Revenue

$      498,066

$             470,845

$         954,537

$         904,849

Cost of revenue

453,305

422,660

872,581

816,308

Selling, general, and administrative expenses

29,740

25,605

61,699

49,427

Operating income

15,021

22,580

20,257

39,114

Interest expense, net

(1,963)

(2,253)

(3,643)

(4,186)

Income from operations before income taxes

13,058

20,327

16,614

34,928

Income tax expense

2,586

4,393

3,287

6,946

Net income

$         10,472

$               15,934

$           13,327

$           27,982

Earnings per share

Basic

$           0.89

$                   1.36

$               1.13

$               2.40

Diluted

$           0.88

$                   1.35

$               1.12

$               2.37

Weighted average common shares
outstanding – basic

11,826

11,715

11,793

11,681

Weighted average common shares
outstanding – diluted

11,954

11,828

11,917

11,823

 

V2X, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

July 1,

December 31,

(In
thousands, except per share information)

2022

2021

Assets

Current assets

Cash and cash equivalents

$                   31,760

$                   38,513

Restricted cash

3,311

__—_

Receivables

374,980

348,605

Prepaid expenses

26,262

21,160

Other current assets

10,646

15,062

Total current assets

446,959

423,340

Property, plant, and equipment, net

23,530

23,758

Goodwill

321,734

321,734

Intangible assets, net

62,159

66,582

Right-of-use assets

39,705

43,651

Other non-current assets

11,760

10,394

Total non-current assets

458,888

466,119

Total Assets

$                 905,847

$                 889,459

Liabilities and Shareholders’ Equity

Current liabilities

Accounts payable

$                 244,080

$                 212,533

Compensation and other employee benefits

82,534

80,284

Short-term debt

10,400

10,400

Other accrued liabilities

48,322

55,031

Total current liabilities

385,336

358,248

Long-term debt, net

78,884

94,246

Deferred tax liability

32,489

32,214

Operating lease liability

30,719

34,536

Other non-current liabilities

14,941

20,128

Total non-current liabilities

157,033

181,124

Total liabilities

542,369

539,372

Commitments and contingencies (Note 9)

Shareholders’ Equity

Preferred stock; $0.01 par value; 10,000,000
shares authorized; No shares issued and outstanding

Common stock; $0.01 par value; 100,000 shares
authorized; 11,846 and 11,738 shares issued and
outstanding as of July 1, 2022, and December 31,
2021, respectively                                      

118

117

Additional paid in capital

91,464

88,116

Retained earnings

281,081

267,754

Accumulated other comprehensive loss

(9,185)

(5,900)

Total shareholders’ equity

363,478

350,087

Total Liabilities and Shareholders’ Equity

$                 905,847

$                 889,459

 

V2X, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Six Months Ended

July 1,

July 2,

(In
thousands)

2022

2021

Operating activities

Net income

$              13,327

$              27,982

Adjustments to reconcile net income to net cash provided by
operating activities:

Depreciation expense

3,238

3,097

Amortization of intangible assets

4,423

4,891

(Gain) Loss on disposal of property, plant, and equipment

(15)

60

Stock-based compensation

4,725

4,923

Amortization of debt issuance costs

388

463

Changes in assets and liabilities:

Receivables

(29,302)

(38,882)

Prepaid expenses

(5,321)

(4,660)

Other assets

5,185

597

Accounts payable

32,470

18,784

Deferred taxes

370

Compensation and other employee benefits

2,507

11,285

Other liabilities

(11,989)

(14,884)

Net cash provided by operating activities

19,636

14,026

Investing activities

Purchases of capital assets

(3,492)

(4,833)

Proceeds from the disposition of assets

18

16

Business acquisition purchase price adjustment

262

Contribution to joint venture

(2,113)

(1,846)

Net cash used in investing activities

(5,587)

(6,401)

Financing activities

Repayments of long-term debt

(5,200)

(4,000)

Proceeds from revolver

392,000

215,000

Repayments of revolver

(402,000)

(215,000)

Proceeds from exercise of stock options

370

113

Payment of debt issuance costs

(458)

(17)

Payments of employee withholding taxes on share-based
compensation

(1,696)

(2,272)

Net cash used in financing activities

(16,984)

(6,176)

Exchange rate effect on cash

(507)

(373)

Net change in cash, cash equivalents and restricted cash

(3,442)

1,076

Cash, cash equivalents and restricted cash – beginning of year

38,513

68,727

Cash, cash equivalents and restricted cash – end of period

$              35,071

$              69,803

Supplemental disclosure of cash flow information:

Interest paid

$                3,409

$                3,111

Income taxes paid

$                6,112

$                5,747

Purchase of capital assets on account

$                    13

$                   618

Key Performance Indicators and Non-GAAP Measures

The primary financial performance measures we use to manage our business and monitor results of operations are revenue trends and operating income trends. Management believes that these financial performance measures are the primary drivers for our earnings and net cash from operating activities. Management evaluates its contracts and business performance by focusing on revenue, operating income, and operating margin. Operating income represents revenue less both cost of revenue and selling, general and administrative (SG&A) expenses. Cost of revenue consists of labor, subcontracting costs, materials, and an allocation of indirect costs, which includes service center transaction costs. SG&A expenses consist of indirect labor costs (including wages and salaries for executives and administrative personnel), bid and proposal expenses and other general and administrative expenses not allocated to cost of revenue. We define operating margin as operating income divided by revenue.

We manage the nature and amount of costs at the program level, which forms the basis for estimating our total costs and profitability. This is consistent with our approach for managing our business, which begins with management’s assessing the bidding opportunity for each contract and then managing contract profitability throughout the performance period.

In addition to the key performance measures discussed above, we consider adjusted operating income, adjusted operating margin, adjusted net income, adjusted diluted earnings per share, EBITDA, adjusted EBITDA, EBITDA margin, adjusted EBITDA margin, and organic revenue to be useful to management and investors in evaluating our operating performance, and to provide a tool for evaluating our ongoing operations. This information can assist investors in assessing our financial performance and measures our ability to generate capital for deployment among competing strategic alternatives and initiatives. We provide this information to our investors in our earnings releases, presentations, and other disclosures.

Adjusted operating income, adjusted operating margin, adjusted net income, adjusted diluted earnings per share, EBITDA, adjusted EBITDA, EBITDA margin, adjusted EBITDA margin, and organic revenue, however, are not measures of financial performance under GAAP and should not be considered a substitute for operating income, operating margin, net income, and diluted earnings per share as determined in accordance with GAAP.  Definitions and reconciliations of these items are provided below.

  • Adjusted
    operating income
     is defined as operating income, adjusted to exclude items that may include, but are not limited to significant charges or credits, and unusual and infrequent non-operating items, such as M&A, integration and related costs, LOGCAP V pre-operational legal costs, and amortization of acquired intangible assets that impact current results but are not related to our ongoing operations.
  • Adjusted
    operating margin
     is defined as adjusted operating income divided by revenue.
  • Adjusted
    net income
     is defined as net income, adjusted to exclude items that may include, but are not limited to, significant charges or credits, and unusual and infrequent non-operating items, such as M&A, integration and related costs, LOGCAP V pre-operational legal costs, and amortization of acquired intangible assets that impact current results but are not related to our ongoing operations.
  • Adjusted
    diluted earnings per share
     is defined as adjusted net income divided by the weighted average diluted common shares outstanding.
  • EBITDA is defined as operating income, adjusted to exclude depreciation and amortization.
  • Adjusted
    EBITDA
     is defined as EBITDA, adjusted to exclude items that may include, but are not limited to, significant charges or credits and unusual and infrequent non-operating items, such as M&A, integration and related costs, LOGCAP V pre-operational legal costs that impact current results but are not related to our ongoing operations.
  • EBITDA
    margin
     is defined as EBITDA divided by revenue.
  • Adjusted
    EBITDA margin
     is defined as Adjusted EBITDA divided by revenue.

 

Adjusted Net Income, Adjusted Diluted Earnings Per
Share (Non-GAAP Measures)

($K,
except per share data)

Three Months
Ended July
01, 2022 As
Reported

M&A,
Integration

and Related
Costs

LOGCAP V
Pre-

Operational

Legal Costs

Amortization
of Acquired
Intangible

Assets

Three
Months

Ended July
01, 2022 –
Adjusted

Revenue

$       498,066

$                      —

$                     —

$                     —

$       498,066

Growth

5.8 %

5.8 %

Operating income

$         15,021

$                5,879

$                     —

$          2,122

$         23,022

Operating margin

3.0 %

4.6 %

Interest expense, net

$          (1,963)

$                      —

$                     —

$                     —

$          (1,963)

Income from operations before income taxes

$            13,058

$                5,879

$                     —

$               2,122

$         21,059

Income tax expense

$               2,586

$                1,164

$                     —

$                  420

$           4,170

Income tax rate

19.8 %

19.8 %

Net income

$            10,472

$                4,715

$                     —

$               1,702

$         16,889

Weighted average common shares outstanding, diluted

11,954

11,954

Diluted earnings per share

$              0.88

$                  0.39

$                     —

$                 0.14

$             1.41

EBITDA (Non-GAAP Measures)

($K)

Three Months
Ended July
01, 2022 As
Reported

M&A,
Integration

and Related
Costs

LOGCAP V
Pre-

Operational

Legal Costs

Amortization
of Acquired
Intangible

Assets

Three
Months

Ended July
01, 2022 –
Adjusted

Operating Income

$         15,021

$                5,879

$                     —

$               2,122

$         23,022

Add:

Depreciation and amortization

$        3,769

$                      —

$                     —

$               (2,122)

$           1,647

EBITDA

$         18,790

$                5,879

$                     —

$                     —

$         24,669

EBITDA Margin

3.8 %

5.0 %

 

Adjusted Net Income, Adjusted Diluted Earnings Per
Share (Non-GAAP Measures)

($K,
except per share data)

Three Months
Ended July
02, 2021 As
Reported

M&A,
Integration

and Related
Costs

LOGCAP V
Pre-

Operational

Legal Costs

Amortization
of Acquired
Intangible Assets

Three Months
Ended July
02, 2021 –
Adjusted

Revenue

$       470,845

$                     —

$                     —

$                     —

$       470,845

Operating income

$      22,580

$                     —

$                   21

$               2,436

$         25,037

Operating margin

4.8 %

5.3 %

Interest expense, net

$          (2,253)

$                     —

$                     —

$                     —

$          (2,253)

Income from operations before income taxes

$         20,327

$                     —

$                   21

$               2,436

$         22,784

Income tax expense

$            4,393

$                     —

$                     4

$                   463

$           4,860

Income tax rate

21.6 %

21.3 %

Net income

$         15,934

$                     —

$                   17

$               1,973

$         17,924

Weighted average common shares outstanding, diluted

11,828

11,828

Diluted earnings per share

$              1.35

$                     —

$                 0.00

$                 0.17

$              1.52

EBITDA (Non-GAAP Measures)

($K)

Three Months
Ended July
02, 2021 As
Reported

M&A,
Integration

and

Related Costs

LOGCAP V
Pre-

Operational

Legal Costs

Amortization
of Acquired
Intangible Assets

Three Months
Ended July
02, 2021 –
Adjusted

Operating Income

$         22,580

$                     —

$                   21

$               2,436

$         25,037

Add:

Depreciation and amortization

$            3,991

$                     —

$                     —

$            (2,436)

$           1,555

EBITDA

$         26,571

$                     —

$                   21

$                     —

$         26,592

EBITDA Margin

5.6 %

5.6 %

 

Adjusted Net Income, Adjusted Diluted Earnings Per
Share (Non-GAAP Measures)

($K,
except per share data)

Six Months
Ended July
01, 2022 As
Reported

M&A,
Integration and
Related Costs

LOGCAP V
Pre-

Operational

Legal Costs

Amortization
of Acquired
Intangible Assets

Six Months
Ended July
01, 2022 –
Adjusted

Revenue

$       954,537

$                     —

$                     —

$                     —

$      954,537

Growth

5.5 %

5.5 %

Operating income

$         20,257

$             14,947

$                   —

$               4,423

$        39,627

Operating margin

2.1 %

4.2 %

Interest expense, net

$          (3,643)

$                     —

$                     —

$                     —

$         (3,643)

Income from operations before income taxes

$         16,614

$             14,947

$                   —

$               4,423

$        35,984

Income tax expense

$            3,287

$               2,957

$                     —

$                    875

$          7,119

Income tax rate

19.8 %

19.8 %

Net income

$              13,327

$             11,990

$                   —

$               3,548

$        28,865

Weighted average common shares outstanding, diluted

11,917

11,917

Diluted earnings per share

$              1.12

$                 1.01

$                 —

$                 0.30

$             2.42

EBITDA (Non-GAAP Measures)

($K)

Six Months
Ended July
01, 2022 As
Reported

M&A,
Integration and
Related Costs

LOGCAP V
Pre-

Operational

Legal Costs

Amortization
of Acquired
Intangible Assets

Six Months
Ended July
01, 2022 –
Adjusted

Operating Income

$         20,257

$             14,947

$                   —

$               4,423

$        39,627

Add:

Depreciation and amortization

$            7,661

$                     —

$                     —

$                (4,423)

$            3,238

EBITDA

$         27,918

$             14,947

$                   —

$                     —

$        42,865

EBITDA Margin

2.9 %

4.5 %

 

Adjusted Net Income, Adjusted Diluted Earnings Per
Share (Non-GAAP Measures)

($K,
except per share data)

Six Months
Ended July
02, 2021 As
Reported

M&A,
Integration and
Related Costs

LOGCAP V
Pre-

Operational

Legal Costs

Amortization
of Acquired
Intangible Assets

Six Months
Ended July
02, 2021 –
Adjusted

Revenue

$      904,849

$                    —

$                    —

$                    —

$      904,849

Operating income

$        39,114

$                     —

$                 178

$              4,891

$        44,183

Operating margin

4.3 %

4.9 %

Interest expense, net

$         (4,186)

$                    —

$                    —

$                    —

$         (4,186)

Income from operations before income taxes

$        34,928

$                     —

$                 178

$              4,891

$        39,997

Income tax expense

$          6,946

$                     —

$                   34

$                 929

$          7,909

Income tax rate

19.9 %

19.9 %

Net income

$        27,982

$                     —

$                 144

$              3,962

$        32,088

Weighted average common shares outstanding, diluted

11,823

11,823

Diluted earnings per share

$             2.37

$                     —

$                0.01

$                0.33

$             2.71

EBITDA (Non-GAAP Measures)

($K)

Six Months
Ended July
02, 2021 As
Reported

M&A,
Integration and
Related Costs

LOGCAP V
Pre-

Operational

Legal Costs

Amortization
of Acquired
Intangible Assets

Six Months
Ended July
02, 2021 –
Adjusted

Operating Income

$        39,114

$                     —

$                 178

$              4,891

$        44,183

Add:

Depreciation and amortization

$          7,988

$                    —

$                    —

$           (4,891)

$          3,097

EBITDA

$        47,102

$                     —

$                 178

$                    —

$        47,280

EBITDA Margin

5.2 %

5.2 %

 

 

SUPPLEMENTAL INFORMATION

Revenue by client branch, contract type, contract relationship, and geographic region for the periods presented below was as follows: 

Revenue
by Client

Three Months Ended

Six Months Ended

July 1,

July 2,

July 1,

July 2,

(In
thousands)

2022

%

2021

%

2022

%

2021

%

Army

$    326,756

65 %

$    310,638

66 %

$     606,869

63 %

$      567,987

63 %

Air Force

68,457

14 %

63,206

13 %

129,930

14 %

141,375

16 %

Navy

64,885

13 %

56,399

12 %

140,102

15 %

112,827

12 %

Other

37,968

8 %

40,602

9 %

77,636

8 %

82,660

9 %

Total revenue

$    498,066

$    470,845

$     954,537

$      904,849

Revenue
by Contract Type

Three Months Ended

Six Months Ended

July 1,

July 2,

July 1,

July 2,

(In
thousands)

2022

%

2021

%

2022

%

2021

%

Cost-plus and cost-reimbursable

$    355,559

71 %

$    344,189

73 %

$     666,653

70 %

$      634,420

70 %

Firm-fixed-price

128,348

26 %

111,416

24 %

256,352

27 %

240,173

27 %

Time and material

14,159

3 %

15,240

3 %

31,532

3 %

30,256

3 %

Total revenue

$    498,066

$    470,845

$     954,537

$      904,849

Revenue
by Contract Relationship

Three Months Ended

Six Months Ended

July 1,

July 2,

July 1,

July 2,

(In
thousands)

2022

%

2021

%

2022

%

2021

%

Prime contractor

$    468,453

94 %

$    440,040

93 %

$     895,546

94 %

$      843,303

93 %

Subcontractor

29,613

6 %

30,805

7 %

58,991

6 %

61,546

7 %

Total revenue

$    498,066

$    470,845

$     954,537

$      904,849

Revenue
by Geographic Region

Three Months Ended

Six Months Ended

July 1,

July 2,

July 1,

July 2,

(In
thousands)

2022

%

2021

%

2022

%

2021

%

Middle East

$    250,222

50 %

$    258,488

55 %

$     485,313

51 %

$      498,500

55 %

United States

158,719

32 %

146,549

31 %

325,454

34 %

296,362

33 %

Europe

42,739

9 %

36,084

8 %

81,178

8 %

76,706

8 %

Asia

46,386

9 %

29,724

6 %

62,592

7 %

33,281

4 %

Total revenue

$    498,066

$    470,845

$     954,537

$      904,849

CONTACT: 
V2X, Inc. 
Mike Smith, CFA
719-637-5773

 


Release – Comstock Announces Second Quarter 2022 Results



Comstock Announces Second Quarter 2022 Results

Research, News, and Market Data on Comstock Mining

Cellulosic
Breakthrough Unlocks Massive New Feedstock Model for Net Zero Energy
Independence

VIRGINIA
CITY, NEVADA, AUGUST 9, 2022
 – Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced its recent business development highlights, second quarter 2022 results, and updated outlook.  

Selected Strategic Highlights – Cellulosic Fuels

  • Expanded our leading cellulosic fuels technology portfolio by filing for a new patent covering breakthrough pathways to produce Bioleum a renewable offset for petroleum and multiple drop-in renewable fuels from woody biomass.
  • Filed a preliminary application for a U.S. Department of Energy (“DOE”) grant opportunity for a pilot scale system to validate enhanced production metrics of purified bio-intermediaries and renewable fuels from woody biomass.
  • Received a notification of “encouragement” from the U.S. Department of Energy for this same grant opportunity.
  • Established strategic collaborations with leading industry partners, including feedstock and offtake relationships, for the development of renewable fuels, from woody biomass, at dramatically improved yield, efficiency, and cost.
  • Advanced the engineering and development of our cellulosic fuel demonstration facility.

Selected Strategic Highlights – Lithium Extraction
and Electrification Products

  • Commissioned our proprietarylithium-ion battery (“LIB”) pilot crushing, separation, and conditioning system.
  • Enhanced the design and commenced upgrades on our proprietary LIB pilot crushing and separation system.
  • Completed construction of our prototype lithium extraction system in our R&D facility and commenced testing.
  • Advanced permitting for our state-of-the-art battery metal recycling facility in Nevada.
  • Production of high-purity black mass to commence in our battery metal recycling facility by Q2 2023.
  • Production of battery grade lithium carbonate to commence in our battery metal recycling facility by Q3 2023.

Selected Financial Highlights

  • Total assets were $117,826,063 as of June 30, 2022, as compared to $115,119,393 at March 31, 2022.
  • Operating expenses were $5,896,617 for the second quarter 2022, including selling, general and administrative expenses of $2,508,573 and research and development expenses of $2,579,150, and depreciation of $808,894.
  • Second quarter 2022 net loss was $13,766,846 or $(0.20) per share, as compared to second quarter 2021 net loss of $6,320,992 or $(0.15) per share. The 2022 results were primarily driven by increases in research and development expenditures and changes in fair values of derivatives.
  • Advanced non-strategic asset monetization efforts with asset sales proceeds expected at $20 million. 
  • Debt was $4,572,356 on June 30, 2022, net of discount, representing an unsecured promissory note.
  • Cash and cash equivalents were $4,345,315 on June 30, 2022.
  • Outstanding common shares were 76,822,049 at June 30, 2022, and 78,737,632 at August 8, 2022.

“Our financial results reflect the impact of our continued investment in the research, development and commercialization of our renewable energy businesses,” said Corrado De Gasperis, Comstock’s executive chairman and chief executive officer. “The building and operating of these proprietary demonstration systems are critical prerequisites for full scale commercialization.”

Cellulosic Fuels

The Company recently announced a significant expansion of its leading cellulosic technology portfolio by filing for a new patent covering breakthrough pathways to produce renewable diesel, sustainable aviation fuel (“SAF”) gasoline and marine fuel from woody biomass, at dramatically improved yield, efficiency, and cost in comparison to all known methods.

Renewable fuels provide a critical opportunity for decarbonization, however, most of the existing U.S. renewable fuel refineries draw from the same limited pool of constrained feedstocks. Comstock’s plans to decarbonize with renewable fuels involves abundant feedstocks that are not used today, enabling a vast untapped energy source with superior benefits. 

“Our new patent covers processes and compositions that have been validated at our existing two ton per day cellulosic fuels pilot facility, verifying that we can simultaneously produce multiple purified biointermediates that are uniquely isolated and free of the contaminants that have frustrated prior attempts at commercializing cellulosic fuel technologies,” added De Gasperis.

Based on current data, Comstock projects best-in-class renewable yields exceeding 80 gallons per dry ton of woody biomass (on a gasoline gallon equivalent basis), with lifecycle greenhouse gas emissions reductions exceeding 80% over petroleum.

The Company is currently expanding its existing cellulosic demonstration systems to include the production of Bioleum™ and expects these demonstration systems to add to our existing capabilities for producing carbon-neutral pulps, cellulosic sugar and cellulosic ethanol.  The expansion into Bioleum™ will demonstrate the full capability of producing these bio-intermediaries suitable for the production of renewable diesel, marine, SAF and gasoline from woody biomass.

The Company recently submitted a preliminary grant application to the U.S. Department of Energy (“DOE”) entitled “Production of Renewable Diesel,
Sustainable Aviation Fuel, Gasoline, and Marine Fuel from Lignocellulosic
Biomass at Dramatically Improved Yield, Efficiency, and Cost” 
and received a DOE notification of encouragement to apply for this funding opportunity, reflecting positively on the Company technology readiness and the strength of its collaboration partners.

De Gasperis continued, “The existing U.S. biorefining capacity is far greater than current feedstocks can support, and the DOE clearly recognizes the need for expanded feedstocks. We believe that our expanded technology solutions, and the magnitude of feedstocks that they enable, unblock one of the most critical supply chain constraints across the U.S. and global markets.”

Electrification Products

The Company completed construction and initial commissioning of its breakthrough LIB crushing, separating, and conditioning process during the second quarter, successfully confirming the production of highly concentrated “black mass.”

“We have successfully developed a proprietary system that produces a novel and pure black mass, further positioning us for high efficiency metals extraction, starting with lithium,” said Mr. De Gasperis. “Our team is enhancing the pilot system for deployment in Nevada where we will ultimately integrate our black mass production and lithium extraction process in 2023.”  

The Company expects to receive its main operating permit during the fourth quarter of 2022 and complete the submission of its modified air quality permits for our LIB processes at our state-of-the-art, battery metal recycling facility in the third quarter.

“The cleaning and repairs of our facility in Nevada are near complete and truly look outstanding.  The facility can now be readied for the receipt and installations of pilot and demonstration units for crushing, separating and conditioning of our novel black mass and subsequently, our lithium extraction, while the permitting process continues” concluded Mr. De Gasperis.

Corporate

Cash and cash equivalents were $4,345,315 on June 30, 2022. The Company expects over $20 million in proceeds over the next two quarters from the sale of its non-mining properties, non-strategic investments, and collection of advances receivable, including the Daney Ranch for $2.5 million, net, and proceeds from Sierra Springs Opportunity Fund totaling over $18 million.

Conference Call Details

Comstock will host the conference call on Tuesday, August 9, 2022, at 1:15 p.m. PDT  (4:15 p.m. EDT) and the webcast will include a moderated question and answer session following the Company’s prepared remarks.  Please click the link below to register in advance and please join the event at least 10 minutes prior to the scheduled start time. Once registered, you will receive a confirmation email containing information about joining the Webcast. Please 
click here to register in advance.

About
Comstock

Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Forward-Looking
Statements 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future changes in our research and development; and future prices and sales of, and demand for, our products and services. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related call or discussion constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

  Contact
information:

 

 

Comstock Mining Inc.
P.O. Box 1118
Virginia City, NV 89440
www.comstock.inc

Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com

Zach Spencer
Director of External Relations
Tel (775) 847-5272 Ext.151
questions@comstockmining.com

 


Release – Gevo Reports Second Quarter 2022 Financial Results



Gevo Reports Second Quarter 2022 Financial Results

Research, News, and Market Data on Gevo

GEVO
TO HOST CONFERENCE CALL TODAY AT 4:30 P.M. EDT/2:30 P.M. MDT

ENGLEWOOD, Colo., Aug. 08, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the second quarter of 2022 and recent corporate highlights.

Recent Corporate Highlights

  • On July 18, 2022, Gevo signed a financeable fuel sales agreement with American Airlines, Inc. to supply 100 million gallons per year of SAF for five years from Gevo’s future commercial operations. The table below summarizes the supply agreements executed since April 1, 2022:

Recently Announced Sales
Agreements

Date Signed

Customer

Product

Volume (MGPY)

Term (Years)

June 2022

Japan Airlines

SAF

5.3

5

June 2022

Finnair

SAF

7.0

5

July 2022

Aer Lingus

SAF

6.3

5

July 2022

American Airlines

SAF

100.0

5

July 2022

Alaska Airlines

SAF

37.0

5

  • Gevo now has more than 350 million gallons per year (“MGPY”) of financeable SAF and hydrocarbon fuel supply agreements, which based on current market projections and operating assumptions, represent approximately $2.1 billion in expected revenue per year, inclusive of the value of environmental benefits. These types of contracts are expected to assist Gevo in obtaining project debt financing.
  • On June 5th, 2022, Gevo executed a registered direct offering of 33.3 million shares to certain institutional investors. That offering closed on June 8th, 2022, providing net proceeds of $139.0 million. As part of the offering, Gevo issued 33.3 million Series 2022-A Warrants with an exercise price of $4.37 per share.
  • The Company’s Net-Zero 1 project is on schedule and the Company continues to work towards completion of the various milestones for 2022, including, among others, executing certain commercial development, build, own and operate agreements, and selecting an EPC contractor for the project.
  • On July 25, 2022, the Company completed the purchase of approximately 245 acres near Lake Preston, South Dakota for its Net-Zero 1 production facility.
  • Gevo’s renewable natural gas (“RNG”) project in Northwest Iowa is now generating biogas from all three dairies and the RNG produced is expected to ramp toward nameplate capacity of 355,000 MMBtu throughout the second half of 2022.

2022 Second Quarter Financial
Highlights

  • Ended the quarter with cash, cash equivalents, restricted cash and marketable securities of $546.8 million compared to $475.8 million as of the end of Q4 2021
  • Revenue of $0.1 million for the quarter compared to $0.3 million in Q2 2021
  • Loss from operations of $(16.1) million for the quarter compared to $(19.1) million in Q2 2021
  • Non-GAAP cash EBITDA loss1 of $(11.0) million for the quarter compared to $(17.2) million in Q2 2021
  • GAAP net loss per share and non-GAAP adjusted net loss per share2 of $(0.06) for the quarter compared to $(0.09) in Q2 2021

Management Comment

Commenting on the second quarter of 2022 and recent corporate events, Dr. Patrick R. Gruber, Gevo’s Chief Executive Officer, said, “Given our continued success in securing SAF supply agreements as well as the additional interest that we are witnessing in the marketplace, there should not be any question about the potential size of the market for renewable fuels. The opportunities in front of us over the next decade and beyond are large and rapidly growing. Our goal is to build SAF production capacity at a rate that will establish Gevo and its partners as a market leader and powerhouse in the renewable fuels sector. It all starts with NZ1, the engineering and design is going well. Based on what we see today we expect to stay on schedule for the 2025 start-up.” Dr. Gruber also remarked that, “Gevo’s RNG project continues to ramp to nameplate capacity of 355,000 MMBtu. All three dairies are now producing biogas which is then upgraded and injected into the sales pipeline. That RNG is sold into the California market by our marketing partner, BP. We continue to collect the performance data for our application to the California Air Resource Board to receive LCFS credits and the Renewable Fuel Standard Program for RINs.”

Second Quarter 2022 Financial
Results

During the three months ended June 30, 2022, we sold 9 thousand gallons of SAF, isooctane, and isooctene from our Luverne Facility. Revenue decreased $0.3 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, due to the Luverne Facility being operated for the Company’s development projects on a as needed basis.

Cost of goods increased $1.0 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to an increase in direct labor and utility expenses as the Luverne Facility was not fully staffed during the second quarter of 2021 due to the COVID-19 pandemic. The majority of our costs are related to the production of SAF, isooctane, and isooctene as we continue to develop and tailor our Luverne Facility demonstration operations to support our focus on advancing technology, testing and optimizing alternative feedstocks, yeast strains, and unit operations as well as partnership development for integrated GHG reductions. Cost of goods sold also includes a $2.1 million net realizable gain adjustment made to our finished goods and work in process inventory. There were no inventory net realizable value adjustments recorded during the three months ended June 30, 2021, as the Luverne Facility was temporarily shut down due to the COVID-19 pandemic.

Research and development expense increased $0.6 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to an increase of laboratory expenses and additional stock-based compensation expense.

Selling, general and administrative expense increased $4.4 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to increases in personnel costs related to strategic new hiring, stock-based compensation, and professional fees.

Preliminary stage project costs are related to our Verity and future Net-Zero Projects and consist primarily of employee expenses and consulting costs. Preliminary stage project costs decreased $5.2 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily because we began capitalizing our RNG and NZ1 project costs in 2021.

Other operations expense increased $0.6 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily related to unallocated engineering and consulting services.

Depreciation and amortization expense increased $0.3 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to the amortization of our patents.

We incurred no gain (loss) from the change in the fair value of the derivative warrant liability in the three months ended June 30, 2022. The last of the liability warrants expired in February 2022.

There were no significant changes in interest expense during the three months ended June 30, 2022, compared to the three months ended June 30, 2021.

Interest and dividend income increased $0.1 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to the interest earned on our investments partially offset by the amortization of the bond premiums.

Other income (expense) increased $2.7 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to our receipt of $2.9 million from the US Department of Agriculture’s Biofuel Producer Program to support biofuel producers who faced unexpected losses due to the COVID-19 pandemic. The Biofuel Producer Program grants are not tax-exempt.

Non-GAAP cash EBITDA loss3 in the three months ended June 30, 2022, was $(11.0) million, compared with a $(17.2) million non-GAAP cash EBITDA loss in the same period in 2021.

During the six months ended June 30, 2022, net cash used for operating activities was $17.1 million compared to $19.5 million for the six months ended June 30, 2021. The $2.4 million decrease was primarily due to increased costs associated with our production of isobutanol and hydrocarbon products for market development, process technology and related process engineering work. In addition, we had increases in personnel expenses to support the growth in business activity, partnership development and Verity development expenses.

Webcast and Conference Call
Information

Hosting today’s conference call at 4:30 p.m. EDT (2:30 p.m. MDT) will be Dr. Patrick R. Gruber, Chief Executive Officer, L. Lynn Smull, Chief Financial Officer, Tim Cesarek, Chief Commercial Officer, and John Richardson, Director of Investor Relations. They will review Gevo’s financial results and provide an update on recent corporate highlights.

To participate in the live call, please register through the following event weblink: https://register.vevent.com/register/BI82c9f363e71c46baa4a8d5e9764fcdbd. After registering, participants will be provided with a dial-in number and pin.

To listen to the conference call (audio only), please register through the following event weblink: https://edge.media-server.com/mmc/p/65vvqgmx.

A webcast replay will be available two hours after the conference call ends on August 8, 2022. The archived webcast will be available in the Investor Relations section of Gevo’s website at www.gevo.com.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel, and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full lifecycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their lifecycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that it possesses the technology and know-how to convert various carbohydrate feedstocks through a fermentation process into alcohols and then transform the alcohols into renewable fuels and materials, through a combination of its own technology, know-how, engineering, and licensing of technology and engineering from Axens North America, Inc., which yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Gevo believes that Argonne National Laboratory GREET model is the best available standard of scientific based measurement for life cycle inventory or LCI.

Learn more at Gevo’s website: www.gevo.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, whether our fuel sales agreements are financeable, the timing of our Net-Zero 1 project, our financial condition, our results of operation and liquidity, our business development activities, our Net-Zero Projects, our RNG Project, our fuel sales agreements, our plans to develop our business, our ability to successfully develop, construct and finance our operations and growth projects, our ability to achieve cash flow from our planned projects, the ability of our products to contribute to lower greenhouse gas emissions, particulate and sulfur pollution, and other statements that are not purely statements of historical fact These forward-looking statements are made based on the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2021 and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Non-GAAP Financial Information

This press release contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), including non-GAAP cash EBITDA loss, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share. Non-GAAP cash EBITDA loss excludes depreciation and amortization and non-cash stock-based compensation from GAAP loss from operations. Non-GAAP adjusted net loss and adjusted net loss per share exclude non-cash gains and/or losses recognized in the quarter due to the changes in the fair value of certain of Gevo’s financial instruments, such as warrants, convertible debt and embedded derivatives, from GAAP net loss. Management believes these measures are useful to supplement its GAAP financial statements with this non-GAAP information because management uses such information internally for its operating, budgeting and financial planning purposes. These non-GAAP financial measures also facilitate management’s internal comparisons to Gevo’s historical performance as well as comparisons to the operating results of other companies. In addition, Gevo believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management as a basis for its financial and operational decision making. Non-GAAP information is not prepared under a comprehensive set of accounting rules and therefore, should only be read in conjunction with financial information reported under U.S. GAAP when understanding Gevo’s operating performance. A reconciliation between GAAP and non-GAAP financial information is provided in the financial statement tables below.

1Cash EBITDA
loss is a non-GAAP measure calculated by adding back depreciation and
amortization and non-cash stock-based compensation to GAAP loss from
operations. A reconciliation of cash EBITDA loss to GAAP loss from operations
is provided in the financial statement tables following this release.

2Adjusted net loss per share is a non-GAAP measure calculated by
adding back non-cash gains and/or losses recognized in the quarter due to the
changes in the fair value of certain of our financial instruments, such as warrants,
convertible debt and embedded derivatives, to GAAP net loss per share. A
reconciliation of adjusted net loss per share to GAAP net loss per share is
provided in the financial statement tables following this release.

3 Cash EBITDA loss is a non-GAAP measure calculated by adding
back depreciation and amortization and non-cash stock compensation to GAAP loss
from operations. A reconciliation of cash EBITDA loss to GAAP loss from
operations is provided in the financial statement tables following this release.


Gevo, Inc.

Condensed Consolidated Balance Sheets Information
(Unaudited, in thousands, except share and per share
amounts)

 

As of June 30, 2022

 

As of December 31, 2021

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

172,984

 

 

$

40,833

 

Marketable securities (current)

 

297,631

 

 

 

275,340

 

Restricted cash (current)

 

5,894

 

 

 

25,032

 

Accounts receivable, net

 

188

 

 

 

978

 

Inventories

 

2,649

 

 

 

2,751

 

Prepaid expenses and other current assets

 

5,275

 

 

 

3,607

 

Total current assets

 

484,621

 

 

 

348,541

 

Property, plant and equipment, net

 

176,054

 

 

 

139,141

 

Long-term marketable securities

 

 

 

 

64,396

 

Long-term restricted cash

 

70,256

 

 

 

70,168

 

Operating right-of-use assets

 

2,098

 

 

 

2,414

 

Finance right-of-use assets

 

27,477

 

 

 

27,297

 

Intangible assets, net

 

8,364

 

 

 

8,938

 

Deposits and other assets

 

5,741

 

 

 

5,581

 

Total assets

$

774,611

 

 

$

666,476

 

 

 

 

 

Liabilities

 

 

 

Current liabilities

 

 

 

Accounts payable and accrued liabilities

$

18,750

 

 

$

28,288

 

Operating lease liabilities (current)

 

423

 

 

 

772

 

Finance lease liabilities (current)

 

6,293

 

 

 

3,413

 

Loans payable – other (current)

 

158

 

 

 

158

 

Total current liabilities

 

25,624

 

 

 

32,631

 

2021 Bonds payable (long-term)

 

66,853

 

 

 

66,486

 

Loans payable – other (long-term)

 

238

 

 

 

318

 

Operating lease liabilities (long-term)

 

1,786

 

 

 

1,902

 

Finance lease liabilities (long-term)

 

16,342

 

 

 

17,797

 

Other long-term liabilities

 

 

 

 

87

 

Total liabilities

 

110,843

 

 

 

119,221

 

 

 

 

 

Stockholders’ Equity

 

 

 

Common stock, $0.01 par value per share; 500,000,000 and 250,000,000 shares authorized at June 30, 2022, and December 31, 2021, respectively; 235,165,951 and 201,988,662 shares issued and outstanding at June 30, 2022, and December 31, 2021, respectively.

 

2,353

 

 

 

2,020

 

Additional paid-in capital

 

1,249,880

 

 

 

1,103,224

 

Accumulated other comprehensive loss

 

(2,256

)

 

 

(614

)

Accumulated deficit

 

(586,209

)

 

 

(557,375

)

Total stockholders’ equity

 

663,768

 

 

 

547,255

 

Total liabilities and stockholders’ equity

$

774,611

 

 

$

666,476

 


Gevo, Inc.

Condensed Consolidated Statements of Operations Information
(Unaudited, in thousands, except share and per share
amounts)

 

Three Months Ended June 30, 2022

 

Six Months Ended June 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Revenue and cost of goods
sold

 

 

 

 

 

 

 

Ethanol sales and related products, net

$

71

 

 

$

 

 

$

240

 

 

$

 

Hydrocarbon revenue

 

18

 

 

 

346

 

 

 

81

 

 

 

359

 

Total revenues

 

89

 

 

 

346

 

 

 

321

 

 

 

359

 

Cost of production (including non-cash compensation expense)

 

2,640

 

 

 

1,617

 

 

 

5,730

 

 

 

2,518

 

Depreciation and amortization

 

1,088

 

 

 

1,177

 

 

 

2,179

 

 

 

2,270

 

Total cost of goods sold

 

3,728

 

 

 

2,794

 

 

 

7,909

 

 

 

4,788

 

Gross loss

 

(3,639

)

 

 

(2,448

)

 

 

(7,588

)

 

 

(4,429

)

Operating expenses

 

 

 

 

 

 

 

Research and development expense (including stock-based compensation)

 

1,966

 

 

 

1,332

 

 

 

3,158

 

 

 

2,710

 

Selling, general and administrative expense (including stock-based compensation)

 

9,209

 

 

 

4,846

 

 

 

18,576

 

 

 

8,660

 

Preliminary stage project costs

 

314

 

 

 

5,472

 

 

 

821

 

 

 

8,199

 

Other operations (including stock-based compensation)

 

601

 

 

 

 

 

 

1,190

 

 

 

 

Loss (gain) on disposal of assets

 

 

 

 

4,954

 

 

 

 

 

 

4,954

 

Depreciation and amortization

 

386

 

 

 

46

 

 

 

737

 

 

 

104

 

Total operating expenses

 

12,476

 

 

 

16,650

 

 

 

24,482

 

 

 

24,627

 

Loss from operations

 

(16,115

)

 

 

(19,098

)

 

 

(32,070

)

 

 

(29,056

)

Other income (expense)

 

 

 

 

 

 

 

(Loss) gain from change in fair value of derivative warrant liability

 

 

 

 

43

 

 

 

16

 

 

 

(10

)

Interest expense

 

(2

)

 

 

(6

)

 

 

(4

)

 

 

(11

)

Investment income (loss)

 

78

 

 

 

 

 

 

330

 

 

 

 

Gain on forgiveness of SBA loan

 

 

 

 

641

 

 

 

 

 

 

641

 

Other income (expense), net

 

2,878

 

 

 

167

 

 

 

2,894

 

 

 

126

 

Total other income (expense), net

 

2,954

 

 

 

845

 

 

 

3,236

 

 

 

746

 

Net loss

$

(13,161

)

 

$

(18,253

)

 

$

(28,834

)

 

$

(28,310

)

Net loss per share – basic and diluted

$

(0.06

)

 

$

(0.09

)

 

$

(0.14

)

 

$

(0.15

)

Weighted-average number of common shares outstanding – basic and diluted

 

209,809,994

 

 

 

198,137,420

 

 

 

205,889,651

 

 

 

190,892,223

 


Gevo, Inc.

Condensed Consolidated Statements of Comprehensive Income
(Unaudited, in thousands, except share and per share
amounts)

 

Three months Ended June 30,

 

Six Months Ended June 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

 

 

 

 

 

 

 

 

Net loss

$

(13,161

)

 

$

(18,253

)

 

$

(28,834

)

 

$

(28,310

)

Other comprehensive income (loss)

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities, net of tax

 

(669

)

 

 

(307

)

 

 

(1,643

)

 

 

(307

)

Adjustment for net gain (loss) realized on available-for-sale securities and included in net income, net of tax

 

 

 

 

 

 

 

1

 

 

 

 

Total change in other comprehensive income (loss)

 

(669

)

 

 

(307

)

 

 

(1,642

)

 

 

(307

)

Comprehensive loss

$

(13,830

)

 

$

(18,560

)

 

$

(30,476

)

 

$

(28,617

)


Gevo, Inc.

Condensed Consolidated Statements of Stockholders Equity
Information

(Unaudited, in thousands, except share amounts)

 

For the three months ended June 30, 2022 and
2021

 

Common Stock

 

Paid-In Capital

 

Accumulated Other Comprehensive Loss

 

Accumulated Deficit

 

Stockholders’ Equity

 

Shares

 

Amount

 

 

 

 

Balance, March 31, 2022

201,752,722

 

 

$

2,019

 

 

$

1,107,051

 

 

$

(1,587

)

 

$

(573,048

)

 

$

534,435

 

Issuance of common stock and common stock warrants, net of issuance costs

33,333,336

 

 

 

333

 

 

 

138,675

 

 

 

 

 

 

 

 

 

139,008

 

Non-cash stock-based compensation

 

 

 

 

 

 

4,220

 

 

 

 

 

 

 

 

 

4,220

 

Issuance of common stock under stock plans, net of taxes

79,893

 

 

 

1

 

 

 

(66

)

 

 

 

 

 

 

 

 

(65

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

(669

)

 

 

 

 

 

(669

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

(13,161

)

 

 

(13,161

)

Balance, June 30, 2022

235,165,951

 

 

$

2,353

 

 

$

1,249,880

 

 

$

(2,256

)

 

$

(586,209

)

 

$

663,768

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2021

198,050,449

 

 

$

1,981

 

 

$

1,101,939

 

 

$

 

 

$

(508,229

)

 

$

595,691

 

Issuance of common stock and common stock warrants, net of issuance costs

 

 

 

 

 

 

(45

)

 

 

 

 

 

 

 

 

(45

)

Issuance of common stock upon exercise of warrants

3,700

 

 

 

 

 

 

4

 

 

 

 

 

 

 

 

 

4

 

Non-cash stock-based compensation

 

 

 

 

 

 

858

 

 

 

 

 

 

 

 

 

858

 

Issuance of common stock under stock plans, net of taxes

(89,673

)

 

 

(1

)

 

 

(1,824

)

 

 

 

 

 

 

 

 

(1,825

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

(307

)

 

 

 

 

 

(307

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

(18,253

)

 

 

(18,253

)

Balance, June 30, 2021

197,964,476

 

 

$

1,980

 

 

$

1,100,932

 

 

$

(307

)

 

$

(526,482

)

 

$

576,123

 

 

 

For the six months ended June 30,2022 and
2021

 

Common Stock

 

Paid-In Capital

 

Accumulated Other Comprehensive Loss

 

Accumulated Deficit

 

Stockholders’ Equity

 

Shares

 

Amount

 

 

 

 

Balance, December 31, 2021

201,988,662

 

 

$

2,020

 

 

$

1,103,224

 

 

$

(614

)

 

$

(557,375

)

 

$

547,255

 

Issuance of common stock and common stock warrants, net of issuance costs

33,333,336

 

 

 

333

 

 

 

138,675

 

 

 

 

 

 

 

 

 

139,008

 

Issuance of common stock upon exercise of warrants

4,677

 

 

 

 

 

 

3

 

 

 

 

 

 

 

 

 

3

 

Non-cash stock-based compensation

 

 

 

 

 

 

8,264

 

 

 

 

 

 

 

 

 

8,264

 

Issuance of common stock under stock plans, net of taxes

(160,724

)

 

 

 

 

 

(286

)

 

 

 

 

 

 

 

 

(286

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

(1,642

)

 

 

 

 

 

(1,642

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

(28,834

)

 

 

(28,834

)

Balance, June 30, 2022

235,165,951

 

 

$

2,353

 

 

$

1,249,880

 

 

$

(2,256

)

 

$

(586,209

)

 

$

663,768

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2020

128,138,311

 

 

$

1,282

 

 

$

643,269

 

 

$

 

 

$

(498,172

)

 

$

146,379

 

Issuance of common stock, net of issuance costs

68,170,579

 

 

 

682

 

 

 

456,963

 

 

 

 

 

 

 

 

 

457,645

 

Issuance of common stock upon exercise of warrants

1,866,758

 

 

 

18

 

 

 

1,103

 

 

 

 

 

 

 

 

 

1,121

 

Non-cash stock-based compensation

 

 

 

 

 

 

1,420

 

 

 

 

 

 

 

 

 

1,420

 

Issuance of common stock under stock plans, net of taxes

(211,172

)

 

 

(2

)

 

 

(1,823

)

 

 

 

 

 

 

 

 

(1,825

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

(307

)

 

 

 

 

 

(307

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

(28,310

)

 

 

(28,310

)

Balance, June 30, 2021

197,964,476

 

 

$

1,980

 

 

$

1,100,932

 

 

$

(307

)

 

$

(526,482

)

 

$

576,123

 


Gevo, Inc.

Condensed Consolidated Cash Flow Information
(Unaudited, in thousands)

 

Six Months Ended June 30,

 

 

2022

 

 

 

2021

 

Operating Activities

 

 

 

Net loss

$

(28,834

)

 

$

(28,310

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Loss on disposal of assets

 

 

 

 

4,954

 

(Gain) on forgiveness of SBA Loans

 

 

 

 

(641

)

Stock-based compensation

 

7,945

 

 

 

1,617

 

Depreciation and amortization

 

2,916

 

 

 

2,372

 

Noncash interest expense

 

2,637

 

 

 

 

Other noncash (income) expense

 

352

 

 

 

(41

)

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

790

 

 

 

(320

)

Inventories

 

102

 

 

 

275

 

Prepaid expenses and other current assets, deposits and other assets

 

(1,828

)

 

 

(3,142

)

Accounts payable, accrued expenses and long-term liabilities

 

(1,194

)

 

 

3,768

 

Net cash used in operating
activities

 

(17,114

)

 

 

(19,468

)

Investing Activities

 

 

 

Acquisitions of property, plant and equipment

 

(46,165

)

 

 

(14,167

)

Acquisition of patent portfolio

 

(10

)

 

 

 

Proceeds from sale and maturity of marketable securities

 

169,082

 

 

 

 

Purchase of marketable securities

 

(131,257

)

 

 

(422,362

)

Net cash used in investing
activities

 

(8,350

)

 

 

(436,529

)

Financing Activities

 

 

 

Proceeds from issuance of 2021 Bonds

 

 

 

 

68,995

 

Debt and equity offering costs

 

(10,993

)

 

 

(34,757

)

Proceeds from issuance of common stock and common stock warrants

 

150,000

 

 

 

487,549

 

Proceeds from exercise of warrants

 

3

 

 

 

1,119

 

Net settlement of common stock under stock plans

 

(286

)

 

 

 

Payment of loans payable – other

 

(72

)

 

 

(53

)

Payment of finance lease liabilities

 

(87

)

 

 

 

Net cash provided by
financing activities

 

138,565

 

 

 

522,853

 

Net increase (decrease) in cash and cash equivalents

 

113,101

 

 

 

66,856

 

Cash, cash equivalents and restricted cash at beginning of period

 

136,033

 

 

 

78,338

 

Cash, cash equivalents and restricted cash at end of period

$

249,134

 

 

$

145,194

 


Gevo, Inc.

Reconciliation of GAAP to Non-GAAP Financial Information
(Unaudited, in thousands, except share and per share
amounts)

 

Three Months Ended June 30, 2022

 

Six Months Ended June 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Non-GAAP
Cash EBITDA:

 

 

 

 

 

 

 

Loss from operations

$

(16,115

)

 

$

(19,098

)

 

$

(32,070

)

 

$

(29,056

)

Depreciation and amortization

 

1,474

 

 

 

1,223

 

 

 

2,916

 

 

 

2,374

 

Stock-based compensation

 

3,687

 

 

 

692

 

 

 

 

 

 

 

Non-GAAP cash EBITDA

$

(10,954

)

 

$

(17,183

)

 

$

(29,154

)

 

$

(26,682

)

 

 

 

 

 

 

 

 

Non-GAAP
Adjusted Net Loss:

 

 

 

 

 

 

 

Net Loss

$

(13,161

)

 

$

(18,253

)

 

$

(28,834

)

 

$

(28,310

)

Adjustments:

 

 

 

 

 

 

 

Gain (loss) from change in fair value of derivative warrant liability

 

 

 

 

(43

)

 

 

(16

)

 

 

10

 

Total adjustments

 

 

 

 

(43

)

 

 

(16

)

 

 

10

 

Non-GAAP Net Income (Loss)

$

(13,161

)

 

$

(18,296

)

 

$

(28,850

)

 

$

(28,300

)

Non-GAAP adjusted net loss per share – basic and diluted

$

(0.06

)

 

$

(0.09

)

 

$

(0.14

)

 

$

(0.15

)

Weighted-average number of common shares outstanding – basic and diluted

 

209,809,994

 

 

 

198,137,420

 

 

 

205,889,651

 

 

 

190,892,223

 

 

 

 

 

 

 

 

 

Investor and Media Contact
+1 720-647-9605
IR@gevo.com

 


A Look at Global Inflation and its Causes


Image Credit: Viv Lynch (Flickr)


Inflation is Spiking Around the World – Not Just in the United States

The 9.1% increase in U.S. consumer prices in the 12 months ending in June 2022, the highest in four decades, has prompted many sobering headlines.

Meanwhile, annual inflation in Germany and the U.K. – countries with comparable economies – ran nearly as high: 7.5% and 8.2%, respectively, for the 12 months ending in June 2022. In Spain, inflation has hit 10%.

It might seem like U.S. policies brought on this predicament, but economists like me doubt it because inflation is spiking everywhere, with few exceptions. Rates averaged 9.65% in the 38 largely wealthy countries that belong to the Organization for Economic Cooperation and Development through May 2022.

What revved up those price increases starting in early 2021?

Scarcity Put Pressure on Prices Everywhere

When the COVID-19 pandemic began, demand for computers and other high-tech goods soared as many people switched from working in offices to clocking in at home.

Computer chip manufacturers struggled to keep up, leading to chip shortages and higher prices for a dizzying array of devices and machines requiring them, including refrigerators, cars and smartphones.

It’s not just chips. Many of the goods Americans consume, such as cars, televisions and prescription drugs, are imported from all corners of the world.

This article was republished with
permission from The Conversation, a news site dedicated to sharing ideas from
academic experts. It was written by and represents the research-based opinions
of Christopher Decker, Professor of Economics, University of Nebraska Omaha.

Supply Chain Strains

On top of problems tied to supply and demand changes, there have been major disruptions to how goods move to manufacturers and then onto consumers along what’s known as the supply chain.

Freight disruption, whether by ship, train or truck, has interfered with the delivery of all sorts of goods since 2020. That’s caused the cost of shipping goods to rise sharply.

These massive shipping disruptions have exposed the disadvantages of the popular just-in-time practice for managing inventory.

By keeping as little of the materials needed to make their products on hand, companies become more vulnerable to shortages and transportation snafus. And when manufacturers are unable to make their products quickly, shortages occur and prices surge.

This approach, especially when it involves the reliance on far-flung suppliers, has left businesses much more susceptible to market shocks.

 

Labor Complications

The beginning of the pandemic also sent shock waves through labor markets with lasting effects.

Many businesses either fired or furloughed large numbers of workers in 2020. When governments began to relax restrictions related to the pandemic, many employers found that significant numbers of their former workers were unwilling to return to work.

Whether those workers had chosen to retire early, seek new jobs offering a better work-life balance or become disabled, the results were the same: labor shortages that required higher wages to recruit replacements and retain other employees.

Again, all of these dynamics are occurring globally, not just in the U.S.

War in Ukraine compounded these woes

Russia’s war on Ukraine, which began officially on Feb. 24, 2022, has also exacerbated inflation by interfering with the global supply of fuels and grains.

The conflict’s effects are reverberating around the globe and fueling inflation.

Russia is the world’s second-largest exporter of crude oil. Sanctions against Russian imports, combined with Russia halting oil shipments to European countries in retaliation, has led to disruptions in the global oil market.

As Europe buys more oil from the Middle East, demand for oil from that region increases, prompting price increases. Crude prices jumped from $101 per barrel in late February 2022, to $123 a month later. Prices stayed high for several months but by late July were around $100 a barrel again.

Food prices have increased substantially in the U.S. and elsewhere, partly due to this conflict. Ukraine possesses some of the most fertile soil in the world and is the third-largest exporter of corn.

Russia’s destruction of Ukrainian crops and its blockade of Ukrainian exports have led to significant price increases worldwide for agricultural commodities.


How Will the World Respond?

Support for globalization and international trade has waned in recent years. Given supply chain disruptions and the war in Ukraine fueling inflation, this trend will likely continue.

However, as an economist, I believe the benefits of free and open trade still outweigh current challenges.

In my view, there isn’t anything fundamentally wrong with the globalization that cannot be fixed. But, like quelling inflation and alleviating supply chain bottlenecks, it will take time.


Suggested Content



Fewer Quitters and Fewer Job Openings Suggest a Move Toward Normalcy



What Might be in a Portfolio Allocated for a Republican Majority in the House?





Useful Information on Where CPI Numbers Come From



Powell is Told by President that He is the Face of Inflation

Stay up to date. Follow us:

 

Uranium Investments and The Inflation Reduction Act



Image Credit: Johannes Plenio (Pexels)


Uranium is Reacting to Increasing Demand in the U.S. with Increased Support from Washington

The Senate approved Inflation Reduction Act (IRA) is yet another nod to nuclear energy. As the world is coming around to the idea that a significant, non-weather-dependent energy source is needed, if there is to be a successful transition away from fossil fuels, nuclear, more specifically, uranium fueled power, continues to get the nod from the U.S. Department of Energy (DOE), lawmakers in Washington, green energy groups, and even from countries like Japan and Germany. 

This IRA bill that just passed in the Senate is headed to the House with almost $400 billion in energy security and climate-related programs over the next ten years. It is expected to easily pass without much renegotiation between the two branches of Congress. Below are some specifics on how it will impact the nuclear energy industry and, therefore, uranium investments. 

 

Enriched Tax Credits for Nuclear Energy

There is a provision that improves upon the Zero-Emissions Nuclear Production law, which is a Power Tax Credit specific for nuclear energy producers. It is in the form of a scaled credit based on plant revenue and applies to existing power plants. The program now includes nuclear and would begin in 2024 and end in 2032; it will offer 5x the benefit if labor requirements are adhered to. The 2032 deadline is an extension of the original plan, which was included in Build Back Better.

The IRA provides for a technology-neutral clean energy production credit of 0.3 cents * kWh base rate for ten years starting in 2025. New, to the program is that energy producers (including coal) will receive a 10% credit in addition to any clean energy credit. This benefit does not look at the technology that is producing the energy.

 

High-Assay Low Enrichment Uranium (HALEU)

The version that passed the Senate also includes $700 million for HALEU, which is the fuel expected to be used in the next generation of reactors. This is interesting in that HALEU production is limited to Russia.

The HALEU funding is broken down into three categories and references the Energy Act of 2020:

  • $100M: Licensing and regulation of facilities and transportation packages.
  • $500M: Acquiring or providing HALEU from a stockpile of uranium to produce HALEU, estimating the quantity of HALEU necessary for domestic, commercial use, and developing a consortium to support the availability of HALEU for civilian use.
  • $100M: Support the availability of HALEU for civilian domestic research, development, demonstration, and commercial.


DOE Loans

The bill also includes $250 billion for DOE loans. The loans will help provide funding to smooth the road toward building tomorrow’s carbon-free technology currently in development.

 

Related Investments

There are many non-energy generating U.S. companies involved in the various areas of providing nuclear fuel and even storing spent fuel. Additionally, there is a futures market and ETFs that either work to mimic the price changes in U308 or own uranium outright and store and provide valuation on the trust.


Source: Pennsylvania
State University Radiation Science and Engineering Center (Public Domain)

The chart below is provided as an example of how companies involved in producing uranium, uranium futures, and the ETF that owns the mineral all trade in relation to each other (three-month period).

Energy Fuels (UUUU) is the largest uranium producer in the U.S. and holds more production capacity and uranium resources than any other U.S. producer. A new research report update on Energy Fuels by Noble Capital Markets was released today (August 8). Read it here.


Source: Koyfin

enCore Energy Corp. (ENCUF) is focused on becoming a domestic (USA) uranium producer. It has significant existing resources in the southwest United States and licensed uranium production facilities in Texas; encore holds the largest uranium position in the Grants Mineral Belt and licensed processing capacity to respond quickly to market opportunities. Discover more here.

Peninsula Energy Ltd (PENMF) is a uranium mining and development company. Projects include Lance ISR Uranium Projects located on the north-east flank of the Powder River Basin in Wyoming and Karoo Uranium Projects in South Africa. It has three reportable operating segments, Lance uranium projects, Wyoming USA; Karoo uranium projects, South Africa; and Corporate. More data on Peninsula Energy is available here, and in the video link below.


Take Away

The provisions in the Inflation Reduction Bill, which seems sure to pass the House and be signed into law, would seem to create a tailwind worth several hundred billion to the industry. It also serves as a glowing nod toward nuclear as one important piece to meeting reduced carbon emissions goals.

The IRA bill gives current investors in the related nuclear power and uranium industries a reason to be more bullish and newer investors a reason to react to the possibility of adding stocks of producers, futures contracts, or uranium itself into their portfolios.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Energy and Global Fundamentals Make a Good Case for Owning Western Uranium Stocks



Can You Invest in Uranium Directly?




Peninsula Energy (PENMF) NobleCon18 – Presentation Replay



Energy Fuels (UUUU) NobleCon18 – Presentation Replay

Sources

 

https://www.eia.gov/energyexplained/nuclear/the-nuclear-fuel-cycle.php

https://www.eia.gov/todayinenergy/detail.php?id=51978

https://thebreakthrough.org/articles/advancing-nuclear-energy-report

https://www.whitehouse.gov/wp-content/uploads/2022/08/SAP-H.R.-5376.pdf


Stay up to date. Follow us:

 

Release – Aurania Provides Update on Geological Mapping Program



Aurania Provides Update on Geological Mapping Program

Research, News, and Market Data on Aurania Resources

Toronto, Ontario, August 8, 2022 – Aurania Resources Ltd. (TSXV:
ARU; OTCQB: AUIAF; Frankfurt: 20Q) (“Aurania” or the “Company”) 
is pleased to report that, under the guidance of Senior Technical Advisor, Dr. Steve Garwin, detailed geological mapping at its Tatasham target is progressing and is expected to be completed in the coming weeks. The second phase of mapping at the Company’s Awacha target is planned to start by the end of August.

The purpose of this field work is to apply the Anaconda mapping method to define the drill targets at Tatasham and Awacha. The Anaconda method was developed in the 60’s and 70’s by Anaconda Copper and has led to the discovery and resource expansion of several porphyry copper-gold deposits including the Apala deposit in Ecuador and Cortadera in Chile.  To learn more about the importance of geological mapping and the Anaconda technique, click
here to view a video with Steve Garwin recorded during the GeoHug webinar
series July 2021.

The Company also announces that its Chairman, President and Chief Executive Officer, Dr. Keith Barron (the “Lender”) completed a loan of C$1,000,000 to the Company. The loan is unsecured, bears interest at 2% per annum and matures upon notice of twelve months and one day from the Lender.  The loan will help fund the Company’s working capital and ongoing exploration activities.

Dr. Keith Barron is a related party of the Company by virtue of the fact that he is the Chairman, the President and Chief Executive Officer, a promoter and a principal shareholder of the Company, and as a result, each of the Loan constitutes a “related party transaction” for the purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying upon an exemption from the formal valuation and minority shareholder approval requirements under MI 61-101 in respect of the Related Party Transactions, in reliance on Sections 5.5(a) and 5.7(1) of MI 61-101, respectively, as the fair market value of the Related Party Transaction, collectively, does not exceed 25% of the Company’s market capitalization, as determined in accordance with MI 61-101. The Company did not file a material change report related to the Loan more than 21 days before the expected closing of the Loan as required by MI 61-101, as the Company required the funds from closing on an expedited basis for sound business reasons.

The Loan and the Insider Participation were approved by the members of the board of directors of the Company who are independent for purposes of the Related Party Transactions, being all directors other than Dr. Barron. No special committee was established in connection with the Loan and the Insider Participation, and no materially contrary view or abstention was expressed or made by any director of the Company in relation thereto.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at 
www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  
https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

carolyn.muir@aurania.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.


Release – Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344



Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Research, News, and Market Data on Cocrystal Pharma

BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a subsidiary of London-based Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organization (CRO), to conduct a Phase 2a clinical trial with the Company’s novel, broad-spectrum, orally administered antiviral candidate CC-42344. This candidate represents a new class of investigational medicine designed to directly inhibit replication of the virus for the treatment of pandemic and seasonal influenza A.

“We are highly encouraged by the Phase 1 healthy volunteer trial results received so far and are committed to rapidly advancing this program into a human challenge Phase 2a trial in influenza A-infected subjects,” said Sam Lee, Ph.D., Cocrystal’s President and co-interim CEO. “The fact that influenza virus is constantly mutating against existing influenza antiviral drugs elevates an urgent need for effective antiviral therapeutics. CC-42344 is a broad-spectrum oral PB2 inhibitor that is highly active against drug-resistant influenza A strains. Further clinical development of CC-42344 offers an opportunity to address the need. Open Orphan is a world leader in conducting human challenge clinical trials with antiviral drug candidates, making it an ideal partner for conducting our Phase 2a trial.”

The single-center, double-blind, placebo-controlled Phase 2a human challenge trial is designed to evaluate safety, viral and clinical measures of orally administered 
CC-42344 to subjects challenged with influenza A. The trial is expected to be initiated in the second half of 2023, pending approval from the United Kingdom Medicines and Healthcare Products Regulatory Agency. This study will be conducted at hVIVO’s state-of-the-art facility in the United Kingdom.

Yamin “Mo” Khan, Open Orphan CEO, said, “We are pleased to be working with Cocrystal to evaluate its promising antiviral drug candidate for influenza A. A human challenge trial is an excellent option for Cocrystal, as it can rapidly provide efficacy data at a lower cost than traditional field trials.”

Cocrystal is conducting a Phase 1 study with CC-42344 in healthy subjects in Australia. The Company recently announced pharmacokinetic (PK) data supporting once-daily dosing from the single-ascending dose portion of this study. Enrollment in the multiple-ascending dose portion of the Phase 1 trial is ongoing, with full trial results expected in 2022.

About CC-42344 and
Influenza

CC-42344 is an oral PB2 inhibitor that blocks an essential step of viral replication. CC-42344 was discovered using Cocrystal’s proprietary structure-based drug discovery platform technology. It is specifically designed to be effective against all significant pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus’ replication machinery is targeted. 
CC-42344 targets the influenza polymerase, an essential replication enzyme with several highly essential regions common to multiple influenza strains, including pandemic strains. In
vitro 
testing showed CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu® and Xofluza®, while also demonstrating favorable pharmacokinetic and safety profiles.

The global influenza therapeutics market is projected to reach $9.5 billion by 2027, from $6.6 billion in 2020, growing at a 4.8% CAGR between 2021 and 2027, according to a report published by Precision Reports in June 2022.

About hVIVO and
Open Orphan plc

hVIVO, a subsidiary of Open Orphan plc, is a rapidly growing specialist contract research organization (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and longstanding client base of biopharma companies.

About Cocrystal
Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cocrystal Pharma Cautionary
Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our collaboration with hVIVO to conduct a Phase 2a clinical trial for CC-42344 and the anticipated timeline for the study, the potential design and efficacy of CC-42344, and the demand for products designed to treat influenza and opportunities presented thereby. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the availability of federal government funding and budgetary issues that may arise, the risks and uncertainties arising from any future impact of the COVID-19 pandemic including in Australia, the Russian invasion of Ukraine, and/or inflation and Federal Reserve interest rate increases in response thereto on the global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs such as obtaining the requisite regulatory approvals including from the United Kingdom Medicines and Healthcare Products Regulatory Agency, the ability of the CRO to recruit patients into clinical trials, and the results of the studies for CC-42344. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100

jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378

Jabraham@jqapartners.com

# # #


Primary Logo

Source: Cocrystal Pharma, Inc.

Released August 8,
2022

 


Release – Kratos Receives $20 Million Unmanned Aerial Drone System Production Contract



Kratos Receives $20 Million Unmanned Aerial Drone System Production Contract

Research, News, and Market Data on Kratos Defense & Security Solutions


SAN DIEGO, 
Aug. 08, 2022 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has received an approximate 
$20 million production contract for high performance, jet powered, unmanned aerial target drone systems. Kratos is an industry leader in the development, design and fielding of affordable, high-performance jet powered unmanned aerial drone systems. The unmanned aerial drone systems produced under this contract award will be manufactured in a Kratos production facility. Due to competitive, security-related, and other considerations, no additional information will be provided related to this award.

Steve Fendley, President of Kratos Unmanned Systems Division, said, “We believe that this contract award is representative of Kratos’ industry leading position for certain of the highest performance and most capable jet drone aircraft flying in the world today. Kratos today has multiple active production lines producing approximately 150 target and tactical jet drone aircraft annually, and this new target drone production contract award is a key element of our future expected growth trajectory.”

About Kratos
Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to 
www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 26, 2021, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact: Yolanda White 858-812-7302 Direct

Investor Information:
877-934-4687

investor@kratosdefense.com